Psychemedics Corporation — Cyborg Score 6/10

Solid
Drug Testing & Workplace Wellness Services

Strategic Profile

The company serves employers across industries including petrochemical, transportation, manufacturing, retail, hospitality, gaming, and education; law enforcement agencies; rehabilitation programs; and public entities such as Federal Reserve banks and schools worldwide. The company executed a 1-for-5000 reverse stock split followed by a 5000-for-1 forward stock split effective December 3, 2024, to facilitate delisting from the Nasdaq Capital Market and reduce annual compliance costs exceeding $845,000.

Cyborg Score Rationale

Psychemedics is the globally recognized leader in hair drug testing with a dominant position among Fortune 500 companies, law enforcement agencies, and educational institutions. However, the company's transition to private status and cost-reduction focus limit near-term growth momentum. The company was awarded "Most Innovative Drug Testing Company of the Year" by Acquisition International Magazine in their 2025 Global Excellence Awards.

Top Insights

  • Hair testing offers 90-day detection windows vs. traditional urine tests, creating sticky customer relationships
  • Recently launched ketamine testing and quartile reporting features address emerging drug threats and client analytics needs
  • Strategic delisting reduces annual compliance costs by $845K+ to refocus on core operations and organic growth
  • Dominant market position with Fortune 500 penetration (10%+) and patented proprietary extraction technology provide durable competitive advantage

Named Competitors

  • Urine-based drug testing — Traditional urinalysis screening with shorter detection windows
  • Oral fluid testing — Saliva-based testing with limited historical data capability
  • Integrated lab services — Multi-modal testing platforms bundling various methodologies

Recent Developments

  • (August 2024) Launched new ketamine hair testing service to detect emerging substances amid rising abuse trends
  • (December 2024) Executed reverse/forward stock split effective December 3, 2024 to facilitate delisting from NASDAQ Capital Market
  • (March 2025) Announced launch of innovative Quartile Reporting feature for enhanced client analytics

Open the full interactive Psychemedics Corporation report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →